BeiGene's Nasdaq Ticker Change: A New Chapter Begins
Located in San Mateo, California, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) is taking an exciting step forward in its operations. The company has decided to change its Nasdaq ticker symbol to "ONC" starting January 2. This change signifies BeiGene's continued dedication to providing innovative oncology treatments globally, aligning with its planned name change to BeOne Medicines Ltd.
Emphasizing Commitment to Oncology
John V. Oyler, the Co-Founder, Chairman, and CEO of BeiGene, expressed the sentiment behind this milestone, stating, "As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide." This statement echoes the proud journey of the company as it progresses in developing innovative solutions, particularly in the fields of hematology and solid tumors.
Ongoing Developments and Shareholder Updates
It’s important to note that while the Nasdaq ticker symbol will change, BeiGene’s CUSIP number will remain the same. Additionally, the stock codes and names for its positions in The Stock Exchange of Hong Kong and the Shanghai Stock Exchange will not be altered, ensuring consistency for shareholders. No actions are required from shareholders to adapt to the new ticker symbol.
Upcoming Presentation at the J.P. Morgan Conference
In conjunction with the ticker change, BeiGene is set to participate in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13. At this important industry event, the company aims to showcase its innovative strategies and developments. Investors and interested parties can expect a live webcast of the event, accessible through the investor relations section of the company's website.
About BeiGene: Pioneering in Oncology
BeiGene, which intends to rebrand as BeOne Medicines, is recognized globally for its pursuits in oncology. The company focuses on discovering and developing groundbreaking treatments that improve patient accessibility and affordability. With an expansive pipeline bolstered by both internal resources and strategic partnerships, BeiGene is committed to transforming the landscape of cancer treatment.
Global Impact through Innovation
With a dedicated workforce of nearly 11,000 employees spanning five continents, BeiGene continues to make strides in the pharmaceutical industry. The organization emphasizes not just the development of new drugs, but ensuring that these therapies are available to patients who need them the most. This commitment underlines BeiGene's mission to enhance cancer care worldwide.
Frequently Asked Questions
What is the reason for BeiGene's ticker symbol change?
The change to the Nasdaq ticker symbol to 'ONC' reflects BeiGene’s commitment to oncology and its approach to delivering innovative cancer treatments.
When will the ticker change take effect?
The new Nasdaq ticker symbol 'ONC' will take effect on January 2.
Will shareholders need to take any action due to the ticker change?
No action is required from shareholders to implement the ticker symbol change.
Where can I watch BeiGene's presentation at the J.P. Morgan Conference?
The presentation can be accessed through the investor relations section of BeiGene’s website during the live event.
What is BeiGene's mission as a global oncology company?
BeiGene aims to discover and develop innovative treatments that are more affordable and accessible for cancer patients worldwide.
